Expression and regulation of Cyr61 in human breast cancer cell lines

Miaw Sheue Tsai, Daphne F. Bogart, Patricia Li, Inderjit Mehmi, Ruth Lupu

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

We have shown that Cyr61, an angiogenic regulator, is overexpressed in invasive and metastatic human breast cancer cells and tumor biopsies. We have further demonstrated that Cyr61 promotes acquisition of estrogen-independence and anti-estrogen resistance in vivo in breast cancer cells. Moreover, we have demonstrated that Cyr61 induces tumor formation and tumor vascularization in vivo, events mediated through the activation of the MAPK and the Akt signaling pathways. Here we investigate how Cyr61 expression is regulated in both estrogen receptor (ER)-positive and ER-negative breast cancer cells. We demonstrate that Cyr61 mRNA and protein expression is inducible by estrogen and anti-estrogens in ER-positive breast cancer cells. We show that a labile protein as well as a negative regulator might be involved in Cyr61 expression in estrogen-dependent breast cancer cells. Other important regulators of Cyr61 expression in breast cancer cells that we found are the phorbol ester TPA, vitamin D, and retinoic acid. TPA causes positive regulation of Cyr61 expression in ER-positive MCF-7 cells. Vitamin D induces a transient stimulatory effect on Cyr61 gene expression. Lastly, retinoic acid has a negative effect on Cyr61 expression and downregulates its expression in MCF-7 cells. Interestingly, most of these effects are not seen in aggressive breast cancer cells that do not express ER and express high levels of Cyr61, such as the MDA-MB-231 cells. Our results are in agreement with our knowledge that Cyr61 promotes tumor growth, and that tumor-promoting agents have a positive impact on cells that express low levels of Cyr61, such as the ER-positive breast cancer cells; however, these agents have no significant effect on cells that express high levels of Cyr61. Our findings suggest an association between increased Cyr61 expression and an aggressive phenotype of breast cancer cells.

Original languageEnglish (US)
Pages (from-to)964-973
Number of pages10
JournalOncogene
Volume21
Issue number6
DOIs
StatePublished - Jan 1 2002
Externally publishedYes

Fingerprint

Breast Neoplasms
Cell Line
Estrogen Receptors
Estrogens
MCF-7 Cells
Tretinoin
Vitamin D
Neoplasms
Phorbol Esters
Proteins
Down-Regulation
Phenotype
Biopsy
Gene Expression
Messenger RNA
Growth

Keywords

  • 780
  • Breast cancer
  • Cyr61
  • Estradiol
  • ICI-182
  • Regulation
  • Tamoxifen

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Expression and regulation of Cyr61 in human breast cancer cell lines. / Tsai, Miaw Sheue; Bogart, Daphne F.; Li, Patricia; Mehmi, Inderjit; Lupu, Ruth.

In: Oncogene, Vol. 21, No. 6, 01.01.2002, p. 964-973.

Research output: Contribution to journalArticle

Tsai, Miaw Sheue ; Bogart, Daphne F. ; Li, Patricia ; Mehmi, Inderjit ; Lupu, Ruth. / Expression and regulation of Cyr61 in human breast cancer cell lines. In: Oncogene. 2002 ; Vol. 21, No. 6. pp. 964-973.
@article{a62ae0d12bd343bf849e2c7aa035ab59,
title = "Expression and regulation of Cyr61 in human breast cancer cell lines",
abstract = "We have shown that Cyr61, an angiogenic regulator, is overexpressed in invasive and metastatic human breast cancer cells and tumor biopsies. We have further demonstrated that Cyr61 promotes acquisition of estrogen-independence and anti-estrogen resistance in vivo in breast cancer cells. Moreover, we have demonstrated that Cyr61 induces tumor formation and tumor vascularization in vivo, events mediated through the activation of the MAPK and the Akt signaling pathways. Here we investigate how Cyr61 expression is regulated in both estrogen receptor (ER)-positive and ER-negative breast cancer cells. We demonstrate that Cyr61 mRNA and protein expression is inducible by estrogen and anti-estrogens in ER-positive breast cancer cells. We show that a labile protein as well as a negative regulator might be involved in Cyr61 expression in estrogen-dependent breast cancer cells. Other important regulators of Cyr61 expression in breast cancer cells that we found are the phorbol ester TPA, vitamin D, and retinoic acid. TPA causes positive regulation of Cyr61 expression in ER-positive MCF-7 cells. Vitamin D induces a transient stimulatory effect on Cyr61 gene expression. Lastly, retinoic acid has a negative effect on Cyr61 expression and downregulates its expression in MCF-7 cells. Interestingly, most of these effects are not seen in aggressive breast cancer cells that do not express ER and express high levels of Cyr61, such as the MDA-MB-231 cells. Our results are in agreement with our knowledge that Cyr61 promotes tumor growth, and that tumor-promoting agents have a positive impact on cells that express low levels of Cyr61, such as the ER-positive breast cancer cells; however, these agents have no significant effect on cells that express high levels of Cyr61. Our findings suggest an association between increased Cyr61 expression and an aggressive phenotype of breast cancer cells.",
keywords = "780, Breast cancer, Cyr61, Estradiol, ICI-182, Regulation, Tamoxifen",
author = "Tsai, {Miaw Sheue} and Bogart, {Daphne F.} and Patricia Li and Inderjit Mehmi and Ruth Lupu",
year = "2002",
month = "1",
day = "1",
doi = "10.1038/sj.onc.1205131",
language = "English (US)",
volume = "21",
pages = "964--973",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Expression and regulation of Cyr61 in human breast cancer cell lines

AU - Tsai, Miaw Sheue

AU - Bogart, Daphne F.

AU - Li, Patricia

AU - Mehmi, Inderjit

AU - Lupu, Ruth

PY - 2002/1/1

Y1 - 2002/1/1

N2 - We have shown that Cyr61, an angiogenic regulator, is overexpressed in invasive and metastatic human breast cancer cells and tumor biopsies. We have further demonstrated that Cyr61 promotes acquisition of estrogen-independence and anti-estrogen resistance in vivo in breast cancer cells. Moreover, we have demonstrated that Cyr61 induces tumor formation and tumor vascularization in vivo, events mediated through the activation of the MAPK and the Akt signaling pathways. Here we investigate how Cyr61 expression is regulated in both estrogen receptor (ER)-positive and ER-negative breast cancer cells. We demonstrate that Cyr61 mRNA and protein expression is inducible by estrogen and anti-estrogens in ER-positive breast cancer cells. We show that a labile protein as well as a negative regulator might be involved in Cyr61 expression in estrogen-dependent breast cancer cells. Other important regulators of Cyr61 expression in breast cancer cells that we found are the phorbol ester TPA, vitamin D, and retinoic acid. TPA causes positive regulation of Cyr61 expression in ER-positive MCF-7 cells. Vitamin D induces a transient stimulatory effect on Cyr61 gene expression. Lastly, retinoic acid has a negative effect on Cyr61 expression and downregulates its expression in MCF-7 cells. Interestingly, most of these effects are not seen in aggressive breast cancer cells that do not express ER and express high levels of Cyr61, such as the MDA-MB-231 cells. Our results are in agreement with our knowledge that Cyr61 promotes tumor growth, and that tumor-promoting agents have a positive impact on cells that express low levels of Cyr61, such as the ER-positive breast cancer cells; however, these agents have no significant effect on cells that express high levels of Cyr61. Our findings suggest an association between increased Cyr61 expression and an aggressive phenotype of breast cancer cells.

AB - We have shown that Cyr61, an angiogenic regulator, is overexpressed in invasive and metastatic human breast cancer cells and tumor biopsies. We have further demonstrated that Cyr61 promotes acquisition of estrogen-independence and anti-estrogen resistance in vivo in breast cancer cells. Moreover, we have demonstrated that Cyr61 induces tumor formation and tumor vascularization in vivo, events mediated through the activation of the MAPK and the Akt signaling pathways. Here we investigate how Cyr61 expression is regulated in both estrogen receptor (ER)-positive and ER-negative breast cancer cells. We demonstrate that Cyr61 mRNA and protein expression is inducible by estrogen and anti-estrogens in ER-positive breast cancer cells. We show that a labile protein as well as a negative regulator might be involved in Cyr61 expression in estrogen-dependent breast cancer cells. Other important regulators of Cyr61 expression in breast cancer cells that we found are the phorbol ester TPA, vitamin D, and retinoic acid. TPA causes positive regulation of Cyr61 expression in ER-positive MCF-7 cells. Vitamin D induces a transient stimulatory effect on Cyr61 gene expression. Lastly, retinoic acid has a negative effect on Cyr61 expression and downregulates its expression in MCF-7 cells. Interestingly, most of these effects are not seen in aggressive breast cancer cells that do not express ER and express high levels of Cyr61, such as the MDA-MB-231 cells. Our results are in agreement with our knowledge that Cyr61 promotes tumor growth, and that tumor-promoting agents have a positive impact on cells that express low levels of Cyr61, such as the ER-positive breast cancer cells; however, these agents have no significant effect on cells that express high levels of Cyr61. Our findings suggest an association between increased Cyr61 expression and an aggressive phenotype of breast cancer cells.

KW - 780

KW - Breast cancer

KW - Cyr61

KW - Estradiol

KW - ICI-182

KW - Regulation

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85047698046&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047698046&partnerID=8YFLogxK

U2 - 10.1038/sj.onc.1205131

DO - 10.1038/sj.onc.1205131

M3 - Article

C2 - 11840342

AN - SCOPUS:85047698046

VL - 21

SP - 964

EP - 973

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 6

ER -